Published in Hum Vaccin Immunother on October 28, 2013
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes | NCT00435981
Diabetes Prevention - Immune Tolerance (DIAPREV-IT) | NCT01122446
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" | NCT01030861
Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients (DIA-AID) | NCT00615264
GABAergic system in the endocrine pancreas: a new target for diabetes treatment. Diabetes Metab Syndr Obes (2015) 0.83
Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes. Front Immunol (2016) 0.78
Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice. PLoS One (2015) 0.75
Novel diagnostic and therapeutic approaches for autoimmune diabetes--a prime time to treat insulitis as a disease. Clin Immunol (2014) 0.75
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med (2002) 7.00
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A (2007) 6.44
Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med (1998) 6.13
GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med (2008) 5.74
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest (2002) 5.52
Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol (2003) 5.47
Oral immunotherapy for treatment of egg allergy in children. N Engl J Med (2012) 5.19
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu (1980) 5.03
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA (2007) 4.29
Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes (2004) 4.25
Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 4.15
Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A (2000) 3.89
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
Two genes encode distinct glutamate decarboxylases. Neuron (1991) 3.68
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity (1997) 3.44
Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet (2001) 3.26
Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet (2011) 3.13
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes (1999) 3.00
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med (2012) 2.86
Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci U S A (1994) 2.82
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A (1991) 2.72
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia (2010) 2.65
Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet (1993) 2.63
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc Natl Acad Sci U S A (1990) 2.23
Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet (2000) 2.07
Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med (1996) 2.06
GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med (2012) 2.01
CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes (2007) 1.98
Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A (1991) 1.97
Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol (2010) 1.95
Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A (2010) 1.87
Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes. Sci Transl Med (2013) 1.84
Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol (1993) 1.82
Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology (2006) 1.79
IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1996) 1.71
A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest (2001) 1.70
Prediction of type 1 diabetes in the general population. Diabetes Care (2010) 1.66
ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J (1996) 1.59
Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care (2002) 1.59
Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes (2009) 1.53
Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A (1996) 1.51
Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med (1996) 1.50
No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia (2000) 1.48
Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes (1998) 1.47
Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology (2009) 1.47
Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications (2005) 1.42
Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein. Diabetes (1999) 1.39
The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab (2001) 1.37
Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest (2003) 1.32
Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol (2011) 1.28
Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J Immunol (2002) 1.26
GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun (2005) 1.26
Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes (2008) 1.26
Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care (2004) 1.21
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes (2013) 1.19
Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care (2011) 1.19
HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes (1995) 1.16
Increased expression of GAD65 and GABA in pancreatic beta-cells impairs first-phase insulin secretion. Am J Physiol Endocrinol Metab (2000) 1.14
Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes (1993) 1.13
Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet (1985) 1.13
Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes (1985) 1.13
Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest (1996) 1.11
Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol (2001) 1.08
Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) (1983) 1.06
Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia (2010) 1.05
Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun (2010) 1.04
GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol (2010) 1.02
Preexisting autoantibodies predict efficacy of oral insulin to cure autoimmune diabetes in combination with anti-CD3. Diabetes (2012) 1.02
Islet autoantigens: structure, function, localization, and regulation. Cold Spring Harb Perspect Med (2012) 1.02
Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev (2007) 1.01
Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study. Diabetes Care (1999) 1.01
Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev (2007) 1.00
B cell-directed therapies in type 1 diabetes. Trends Immunol (2011) 0.98
Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev (2007) 0.95
Class III alleles of the variable number of tandem repeat insulin polymorphism associated with silencing of thymic insulin predispose to type 1 diabetes. J Clin Endocrinol Metab (2001) 0.94
GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia (2009) 0.94
Vaccination against self to prevent autoimmune disease: the type 1 diabetes model. Immunol Cell Biol (2008) 0.89
Neonatal tolerization with glutamic acid decarboxylase but not with bovine serum albumin delays the onset of diabetes in NOD mice. Diabetes (1994) 0.88
Class III alleles at the insulin VNTR polymorphism are associated with regulatory T-cell responses to proinsulin epitopes in HLA-DR4, DQ8 individuals. Diabetes (2005) 0.87
Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes (2013) 0.86
Therapy with GAD in diabetes. Diabetes Metab Res Rev (2009) 0.85
Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes. Ann N Y Acad Sci (2004) 0.85
IA-2 and IA-2 beta are major autoantigens in IDDM and the precursors of the 40 kDa and 37 kDa tryptic fragments. J Autoimmun (1996) 0.82
Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome--dosage and kinetics prerequisites. Transplantation (1991) 0.82
Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev (2011) 4.15
Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J Immunol (2003) 0.93
IP-10 and type 1 diabetes: a question of time and location. Autoimmunity (2004) 0.87
Apoptosis of autoreactive CD8 lymphocytes as a potential mechanism for the abrogation of type 1 diabetes by islet-specific TNF-alpha expression at a time when the autoimmune process is already ongoing. Ann N Y Acad Sci (2002) 0.81
Using regulatory APCs to induce/maintain tolerance. Ann N Y Acad Sci (2003) 0.79
Antibody cross-reactivity and the viral aetiology of type 1 diabetes. J Pathol (2013) 0.77
Natural killer T cells: born in the thymus, raised in the gut. Gastroenterology (2012) 0.76